Inflammation and Anti-Inflammatory Therapies for Cystic Fibrosis

Clinics in Chest Medicine

Volumn 28, Issue 2, 2007, Pages 331-346

  Chmiel, James F ^a,b   Konstan, Michael W ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CORTICOSTEROID; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBUPROFEN; ICOSANOID; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY OBSTRUCTION; BACTERIAL INFECTION; BRONCHIECTASIS; CLINICAL TRIAL; CYSTIC FIBROSIS; HUMAN; INFLAMMATION; LUNG DISEASE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SIGNAL TRANSDUCTION;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CYSTIC FIBROSIS; CYTOKINES; DISEASE PROGRESSION; HUMANS; IBUPROFEN; INFLAMMATION; INFLAMMATION MEDIATORS; PROTEASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 34247464737     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2007.02.002     Document Type: Review

References (127)

1. Davis P.B., Drumm M., and Konstan M.W. Cystic fibrosis: state of the art. Am J Respir Crit Care Med 154 5 (1996) 1229-1256
2. Chmiel J.F., Konstan M.W., and Berger M. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 23 1 (2002) 5-27
3. Khan T.Z., Wagener J.S., Bost T., et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151 4 (1995) 1075-1082
4. Bonfield T.L., Panuska J.R., Konstan M.W., et al. Inflammatory cytokines in cystic fibrosis lungs. [Published erratum appears in Am J Respir Crit Care Med 1996 Oct;154(4 Pt 1):1217]. Am J Respir Crit Care Med 152 6 Pt 1 (1995) 2111-2118
5. Kirchner K.K., Wagener J.S., Khan T.Z., et al. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med 154 5 (1996) 1426-1429
6. Konstan M.W., Hilliard K.A., Norvell T.M., et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. [published erratum appears in Am J Respir Crit Care Med 1995 Jan:151(1)260]. Am J Respir Crit Care Med 150 2 (1994) 448-454
7. Konstan M.W., Walenga R.W., Hilliard K.A., et al. Leukotriene B4 is markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 148 4 Pt 1 (1993) 896-901
8. Birrer P., McElvaney N.G., Rudeberg A., et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 150 1 (1994) 207-213
9. Balough K., McCubbin M., Weinberger M., et al. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 20 2 (1995) 63-70
10. Armstrong D.S., Grimwood K., Carzino R., et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 310 6997 (1995) 1571-1572
11. Armstrong D.S., Grimwood K., Carlin J.B., et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 156 4 Pt 1 (1997) 1197-1204
12. Noah T.L., Black H.R., Cheng P.W., et al. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 175 3 (1997) 638-647
13. Muhlebach M.S., Stewart P.W., Leigh M.W., et al. Quantitation of inflammatory response to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 160 1 (1999) 186-191
14. Tager A.M., Wu J., and Vermeulen M.W. The effect of chloride concentration on human neutrophil functions: potential relevance to cystic fibrosis. Am J Respir Cell Mol Biol 19 4 (1998) 643-652
15. Watt A.P., Courtney J., Moore J., et al. Neutrophil cell death, activation and bacterial infection in cystic fibrosis. Thorax 60 8 (2005) 659-664
16. Chmiel J.F., and Davis P.B. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?. Respir Res 4 1 (2003) 8-21
17. Bonfield T.L., Konstan M.W., and Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 104 1 (1999) 72-77
18. Bonfield T.L., Konstan M.W., Burfeind P., et al. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 13 3 (1995) 257-261
19. Balfour-Lynn I.M., Laverty A., and Dinwiddie R. Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child 75 4 (1996) 319-322
20. Grasemann H., Michler E., Wallot M., et al. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 24 3 (1997) 173-177
21. Ollero M., Junaidi O., Zaman M.M., et al. Decreased expression of peroxisome proliferators activated receptor gamma in cftr -/- mice. J Cell Physiol 200 2 (2004) 235-244
22. Green S. PPAR: a mediator of peroxisome proliferators action. Mutat Res 333 1-2 (1995) 101-109
23. Vanden Berghe W., Vermeulen L., Delerive P., et al. A paradigm for gene regulation: inflammation, NF-kappaB, and PPAR. Adv Exp Med Biol 544 (2003) 181-196
24. Davis P.B., Gupta S., Eastman J., et al. Inhibition of proinflammatory cytokine production by PPARgamma agonists in airway epithelial cells. Pediatr Pulmonol Suppl 25 (2003) A246 268-69
25. Auerbach H.S., Williams M., Kirkpatrick J.A., et al. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 2 8457 (1985) 686-688
26. Eigen H., Rosenstein B.J., FitzSimmons S., et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 126 4 (1995) 515-523
27. Konstan M.W., Byard P.J., Hoppel C.L., et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332 13 (1995) 848-844
28. Donati M.A., Haver K., Gerson W., et al. Long-term alternate day prednisone therapy in cystic fibrosis. Pediatr Pulmonol 5 (1990) A322 277
29. Lai H.-C., FitzSimmons S.C., Allen D.B., et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 342 12 (2000) 851-859
30. Greally P., Hussain M.J., Vergani D., et al. Interleukin-1α, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch Dis Child 71 1 (1994) 35-39
31. Cheng K., Ashby D., and Smyth R. Oral steroids for cystic fibrosis. The Cochrane Database Syst Rev 4 (1999) CD000407
32. Oermann C.M., Sockrider M.M., and Konstan M.W. The use of anti-inflammatory medications in cystic fibrosis: trends, and physician attitudes. Chest 115 4 (1999) 1053-1058
33. Konstan M.W., Butler S.M., Schidlow D.V., et al. Patterns of medical practice in cystic fibrosis. Part II: use of therapies. Pediatr Pulmonol 28 4 (1999) 248-254
34. Schiotz P.O., Jorgensen M., Flensborg E.W., et al. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. Acta Paediatr Scand 72 2 (1983) 283-287
35. van Haren E.H.J., Lammers J.-W.J., Festen J., et al. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med 89 3 (1995) 209-214
36. Nikolaizik W.H., and Schoni M.H. Pilot study to assess the effect of inhaled corticosteroids on lung function on patients with cystic fibrosis. J Pediatr 128 2 (1996) 271-274
37. Balfour-Lynn I.M., Klein N.J., and Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 77 2 (1997) 124-130
38. Bisgaard H., Pedersen S.S., Nielsen K.G., et al. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 156 4 pt 1 (1997) 1190-1196
39. Dauletbaev N., Viel K., Behr J., et al. Effects of short-term inhaled fluticasone on oxidative burst of sputum cells in cystic fibrosis patients. Eur Respir J 14 5 (1999) 1150-1155
40. Wojtczak H.A., Kerby G.S., Wagener J.S., et al. Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study. Pediatr Pulmonol 32 4 (2001) 293-302
41. Dezateux C., Walters S., and Balfour-Lynn I. Inhaled corticosteroids for cystic fibrosis. [Cochrane methodology review]. The Cochrane Library issue 4 (2003), John Wiley & Sons, Ltd., Chichester (UK)
42. Balfour-Lynn I.M., Lees B., Hall P., et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 173 12 (2006) 1356-1362
43. Schmidt J., Davidson A.G.F., Seear M., et al. Is the acquisition of pseudomonads in cystic fibrosis patients increased by use of inhaled corticosteroids? Unexpected results from a double blind placebo controlled study. Pediatr Pulmonol Suppl 14 (1997) A318 293-294
44. Konstan M.W., Vargo K.M., and Davis P.B. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection: implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis 141 1 (1990) 186-192
45. Konstan M.W., Krenicky J.E., Finney M.R., et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis. J Pharmacol Exp Ther 306 3 (2003) 1086-1091
46. Scheuren N., Bang H., Munster T., et al. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol 123 4 (1998) 645-652
47. Tegeder I., Niederberger E., Israr E., et al. Inhibition of NF-κB and AP-1 activation by R- and S-flurbiprofen. FASEB J 15 3 (2001) 595-597
48. Tegeder I., Pfeilschifter, and Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15 12 (2001) 2057-2072
49. Jaradat M.S., Wongsud B., Phornchirasilp S., et al. Activation of peroxisome proliferators-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 62 12 (2001) 1587-1595
50. Konstan M.W., Schluchter M.D., Storfer-Isser, et al. Use of ibuprofen for the treatment of airway inflammation in CF: an update. Pediatr Pulmonol Suppl 24 (2002) 164-165
51. Dezateux C., and Crighton A. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. [Cochrane methodology review]. The Cochrane Library issue 4 (2003), John Wiley & Sons, Ltd., Chichester (UK)
52. 1 among young patients with mild lung disease in the CFF Registry. Pediatr Pulmonol Suppl 27 (2004) A385 322
53. Chmiel J.F., Konstan M.W., Saadane A., et al. Prolonged inflammatory response to acute pseudomonas challenge in IL-10 knockout mice. Am J Respir Crit Care Med 165 8 (2002) 1176-1181
54. Chmiel J.F., Konstan M.W., Knesebeck J.E., et al. IL-10 attenuates excessive inflammation in chronic pseudomonas infection in mice. Am J Respir Crit Care Med 160 6 (1999) 2040-2047
55. Kelley T.J., and Drumm M.L. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 102 6 (1998) 1200-1207
56. Kelley T.J., and Elmer H.L. In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium. J Clin Invest 106 3 (2000) 403-410
57. Steagall W.K., Elmer H.L., Brady K.G., et al. Cystic fibrosis transmembrane conductance regulator-dependent regulation of epithelial inducible nitric oxide synthase expression. Am J Respir Cell Mol Biol 22 1 (2000) 45-50
58. Moss R.B., Mayer-Hamblett N., Wagener J., et al. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 39 3 (2005) 209-218
59. Zingarelli B., Sheehan M., Hake P.W., et al. Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 171 12 (2003) 6827-6837
60. Ruan H., Pownall H.J., and Lodish H.F. Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. J Biol Chem 278 30 (2003) 28181-28192
61. Meng Q.H., Springall D.R., Bishop A.E., et al. Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 184 3 (1998) 323-331
62. Kraynack N.C., Corey D.A., Elmer H.L., et al. Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 283 3 (2002) L604-L611
63. Dunzendorfer S., Rothbucher D., Schratzberger P., et al. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 81 6 (1997) 963-969
64. Weber C., Erl W., Weber K.S., et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 30 5 (1997) 1212-1217
65. Rezaie-Majd A., Maca T., Bucek R.A., et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 22 7 (2002) 1194-1199
66. Martin G., Duez H., Blanquart C., et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 107 11 (2001) 1423-1432
67. Zelvyte I., Dominaitiene R., Crisby M., et al. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 45 2 (2002) 147-154
68. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 53 (2002) 409-435
69. Grasemann H., Schwiertz R., Grasemann C., et al. Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis. Respir Res 7 (2006) 87-93
70. Grasemann H., Schwiertz R., Matthiesen S., et al. Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med 172 12 (2005) 1523-1528
71. Hopkins N., Gunning Y., O'Croinin D.F., et al. Anti-inflammatory effect of augmented nitric oxide production in chronic lung infection. J Pathol 209 2 (2006) 198-205
72. Grasemann H., Grasemann C., Kurtz F., et al. Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur Respir J 25 1 (2005) 62-68
73. Cromwell O., Walport M.J., Morris H.R., et al. Identification of leukotrienes D and B in sputum from cystic fibrosis patients. Lancet 2 8239 (1981) 164-165
74. Sampson A.P., Spencer D.A., Green C.P., et al. Leukotrienes in the sputum and urine of cystic fibrosis children. Br J Clin Pharmacol 30 6 (1990) 861-869
75. Ford-Hutchinson A.W., Bray M.A., Doig M.V., et al. A potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286 5770 (1980) 264-265
76. Hubbard R.C., Fells G., Gadek J., et al. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency: spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 88 3 (1991) 891-897
77. 4 receptor antagonist) for the treatment of CF lung disease. Pediatr Pulmonol Suppl 28 (2005) 125-127
78. Stelmach I., Korzeniewska A., Stelmach W., et al. Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis. Ann Allergy Asthma Immunol 95 4 (2005) 372-380
79. Panchaud A., Sauty A., Kernen Y., et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin Nutr 25 3 (2006) 418-427
80. Henderson Jr. W.R., Astley S.J., McCready M.M., et al. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J Pediatr 124 3 (1994) 400-408
81. Velsor L.W., van Heeckeren A., and Day B.J. Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Physiol Lung Cell Mol Physiol 281 1 (2001) L31-L38
82. Jobsis Q., Raatgeep H.C., Schellekens S.L., et al. Hydrogen peroxide and nitric oxide in exhaled air of children with cystic fibrosis during antibiotic treatment. Eur Respir J 16 1 (2000) 95-100
83. Hull J., Vervaart P., Grimwood K., et al. Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax 52 6 (1997) 557-560
84. Sadowska A.M., Manuel-y-Kennoy B., and De Backer W.A. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD. Discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther 20 1 (2007) 9-22
85. Tirouvanziam R., Conrad C.K., Bottiglieri T., et al. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A 103 12 (2006) 4628-4633
86. Linsdell P., and Hanrahan J.W. Glutathione permeability of CFTR. Am J Physiol 275 1 Pt 1 (1998) C323-C326
87. Roum J.H., Buhl R., McElvaney N.G., et al. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 75 6 (1993) 2419-2424
88. Roum J.H., Borok Z., McElvaney N.G., et al. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol 87 1 (1999) 438-443
89. Griese M., Ramakers J., Krasselt A., et al. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am J Respir Crit Care Med 169 7 (2004) 822-828
90. Ferkol T., Cohn L.A., Phillips T.E., et al. Targeted delivery of antiprotease to the epithelial surface of human tracheal xenografts. Am J Respir Crit Care Med 167 10 (2003) 1374-1379
91. McElvaney N.G., Hubbard R.C., Birrer P., et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 337 8738 (1991) 392-394
92. 1-protease inhibitor) in CF. Pediatr Pulmonol 20 6 (1995) 421
93. Bilton D., Elborn S., Conway S., et al. Phase II trial to assess the clinical efficacy of transgenic alpha-1-antitrypsin (tg-hAAT) as an effective treatment of cystic fibrosis. Pediatr Pulmonol Suppl 19 (1999) A289 246
94. Rees D.D., Rogers R.A., Cooley J., et al. Recombinant human monocyte/neutrophil elastase inhibitor protects rat lungs against injury from cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 20 1 (1999) 69-78
95. Grimbert D., Vecellio L., Delepine P., et al. Characteristics of EPI-hNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis. J Aerosol Med 16 2 (2003) 121-129
96. Delacourt C., Herigault S., Delclaux C., et al. Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am J Respir Cell Mol Biol 26 3 (2002) 290-297
97. Honore S., Attalah H.L., Azoulay E., et al. Beneficial effect of an inhibitor of leukocyte elastase (EPI-hNE-4) in presence of repeated lung injuries. Shock 22 2 (2004) 131-136
98. Harris M., Firsov D., Vuagniaux G., et al. A novel neutrophil elastase inhibitor prevents elastase activation and surface cleavage of the epithelial sodium channel expressed in Xenopus laevis oocytes. J Biol Chem 282 1 (2007) 58-64
99. Konstan M.W. Evolving anti-inflammatory therapy in cystic fibrosis. In: Ramsey B.W., and Hodson M.E. (Eds). New insights into cystic fibrosis. vol. 3 no. 2 (1995), Gardiner-Caldwell SynerMen, New Jersey 7-11
100. Ramsey B.W. Management of pulmonary disease in patients with cystic fibrosis. [published erratum appears in N Engl J Med 1996 Oct;335(15):1167]. N Engl J Med 335 3 (1996) 179-188
101. Kudoh S., Azuma A., Yamamoto M., et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 157 6 Pt 1 (1998) 1829-1832
102. Gerhardt S.G., McDyer J.F., Girgis R.E., et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 168 1 (2003) 121-125
103. Jaffe A., Francis J., Rosenthal M., et al. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 351 9100 (1998) 420
104. Wolter J., Seeney S., Bell S., et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57 3 (2002) 212-216
105. Equi A., Balfour-Lynn I.M., Bush A., et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360 9338 (2002) 978-984
106. Saiman L., Marshall B.C., Mayer-Hamblett N., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 13 (2003) 1749-1756
107. Tateda K., Comte R., Pechere J.C., et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 45 6 (2001) 1930-1933
108. Nagino K., and Kobayashi H. Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa. Clin Microbiol Infect 3 4 (1997) 432-439
109. Ichimiya T., Takeoka K., Hiramatsu K., et al. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 42 3 (1996) 186-191
110. Yamasaki T., Ichimiya T., Hirai K., et al. Effect of antimicrobial agents on the piliation of Pseudomonas aeruginosa and adherence to mouse tracheal epithelium. J Chemother 9 1 (1997) 32-37
111. Molinari G., Guzman C.A., Pesce A., et al. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 31 5 (1993) 681-688
112. Culic O., Erakovic V., Cepelak I., et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 450 3 (2002) 277-289
113. Suzuki H., Shimomura A., Ikeda K., et al. Inhibitory effect of macrolides on interleukin-8 secretion from cultured human nasal epithelial cells. Laryngoscope 107 12 Pt 1 (1997) 1661-1666
114. Suzuki H., Asada Y., Ikeda K., et al. Inhibitory effect of erythromycin on interleukin-8 secretion from exudative cells in the nasal discharge of patients with chronic sinusitis. Laryngoscope 109 3 (1999) 407-410
115. Ianaro A., Ialenti A., Maffia P., et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 292 1 (2000) 156-163
116. Feldman C., Anderson R., Theron A.J., et al. Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro. Inflammation 21 6 (1997) 655-665
117. Rubin B.K., and Tamaoki J. Macrolide antibiotics as biological response modifiers. Curr Opin Investig Drugs 1 2 (2000) 169-172
118. Shak S., Capon D.J., Hellmiss R., et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A 87 23 (1990) 9188-9192
119. Shah P.L., Scott S.F., Knight R.A., et al. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 51 2 (1996) 119-125
120. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 331 10 (1994) 637-642
121. Quan J.M., Tiddens H.A., Sy J.P., et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung abnormalities. J Pediatr 139 6 (2001) 813-820
122. Konstan M.W., Wagener J.S., Pasta D.J., et al. Pulmozyme (dornase alfa) use is associated with a slower rate of lung function decline in patients with cystic fibrosis. Pediatr Pulmonol Suppl 29 (2006) A370 337
123. Paul K., Rietschel E., Ballmann M., et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 169 9 (2004) 719-725
124. Ratjen F., Paul K., van Koningsbruggen S., et al. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. Pediatr Pulmonol 39 1 (2005) 1-4
125. Ballmann M., Junge S., and von der Hardt H. Low-dose methotrexate for advanced pulmonary disease in patients with cystic fibrosis. Respir Med 97 5 (2003) 498-500
126. Bhal G.K., Maguire S.A., and Bowler I.M. Use of cyclosporin A as a steroid sparing agent in cystic fibrosis. Arch Dis Child 84 1 (2001) 89
127. Konstan M.W., and Davis P.B. Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev 54 11 (2002) 1409-1423